- Seattle Genetics (NASDAQ:SGEN) is scheduled to announce Q3 earnings results on Thursday, October 28th, after market close.
- The consensus EPS Estimate is -$0.57 and the consensus Revenue Estimate is $384.83M (-63.7% Y/Y).
- Royalty revenue estimate of $33.8M; Adcetris revenue estimate of $176.8M.
- In September, Seeking Alpha contributor William Meyers argued that Seagen's "stock is a buy for its pipeline value", and said that the current revenue and cash support the company's R&D effort.
- Seagen shares rose more than 2% in reaction to reporting second-quarter results that beat Wall Street estimates, helped by sales of its PADCEV and TUKYSA treatments, in July.
- Over the last 1 year, SGEN has beaten EPS estimates 0% of the time and has beaten revenue estimates 100% of the time.
- Over the last 3 months, EPS estimates have seen 2 upward revisions and 3 downward. Revenue estimates have seen 11 upward revisions and 4 downward.
- The company's shares have gained more than 1% year to date.